CN103961391B - A kind of pharmaceutical composition treating gastrointestinal neurosis - Google Patents
A kind of pharmaceutical composition treating gastrointestinal neurosis Download PDFInfo
- Publication number
- CN103961391B CN103961391B CN201410154453.XA CN201410154453A CN103961391B CN 103961391 B CN103961391 B CN 103961391B CN 201410154453 A CN201410154453 A CN 201410154453A CN 103961391 B CN103961391 B CN 103961391B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- gastrointestinal
- treatment
- gastrointestinal neurosis
- neurosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000033041 Somatoform disorder gastrointestinal Diseases 0.000 title claims abstract description 79
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 71
- 239000002775 capsule Substances 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 33
- 241000756943 Codonopsis Species 0.000 claims abstract description 31
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960003439 mebendazole Drugs 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- 229940080926 mebendazole 100 mg Drugs 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000006286 aqueous extract Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 239000011812 mixed powder Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 32
- 230000002496 gastric effect Effects 0.000 abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 201000010099 disease Diseases 0.000 abstract description 24
- 210000005036 nerve Anatomy 0.000 abstract description 9
- 230000004064 dysfunction Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 description 23
- 206010012735 Diarrhoea Diseases 0.000 description 14
- 206010000060 Abdominal distension Diseases 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 11
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 10
- 206010022437 insomnia Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 208000019790 abdominal distention Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 206010000087 Abdominal pain upper Diseases 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 208000010643 digestive system disease Diseases 0.000 description 7
- 208000018685 gastrointestinal system disease Diseases 0.000 description 7
- 210000003097 mucus Anatomy 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 206010010947 Coordination abnormal Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 208000016290 incoordination Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010029333 Neurosis Diseases 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000507 anthelmentic effect Effects 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 201000001352 cholecystitis Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 3
- 230000007661 gastrointestinal function Effects 0.000 description 3
- 230000005176 gastrointestinal motility Effects 0.000 description 3
- 208000015238 neurotic disease Diseases 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000004206 stomach function Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229940125725 tranquilizer Drugs 0.000 description 3
- 239000003204 tranquilizing agent Substances 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000005645 nematicide Substances 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- JVXZRQGOGOXCEC-UHFFFAOYSA-N scutellarein Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C(O)=C(O)C=C2O1 JVXZRQGOGOXCEC-UHFFFAOYSA-N 0.000 description 2
- 230000037321 sleepiness Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003504 ach effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition treating gastrointestinal neurosis.Representing with weight portion, this pharmaceutical composition is by Radix Codonopsis 9～15g, Rhizoma Atractylodis Macrocephalae (parched) 3～12g, the Radix Aucklandiae 3～10g and mebendazole 90～110mg composition.It is capsule that the present invention treats the dosage form of the pharmaceutical composition of gastrointestinal neurosis.The present invention treats the medicine of gastrointestinal neurosis, is for causing the pathogenesis etiology of gastrointestinal nerve dysfunction and advancing of disease and recovery process, from the angle of science by constantly groping to find out.The present invention treats gastrointestinal neurosis medicine and has the advantage for the treatment of both the principal and secondary aspects of a disease, and its effective percentage reaches more than 95%, and cure rate reaches more than 80%.Further, medicine of the present invention have be directed to the cause of disease, formula is simple, treatment time is short, be difficult to recurrence, side effect is little, low cost and other advantages.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition treating gastrointestinal neurosis.
Background technology
Gastrointestinal neurosis: the most common in clinic, is the gastroenteropathy that causes of gastrointestinal nerve dysfunction, the one group of gastrointestinal syndrome itself occurred without organic disease.Medically it is divided into stomach neurosis and intestinal neurosis (irritable bowel syndrome), the most common gastroenteropathy, disease show as more gastric fullness, flatulence, belch, acid regurgitation, abdominal distention, stomachache, constipation or diarrhoea or constipation replace with diarrhoea, feces band mucus, some patient also time be often accompanied by cardiopalmus, tachypnea, uncomfortable in chest, sweating in hand and foot, head battle array heat, dizzy, have a headache, have a sleepless night, menoxenia and the symptom of the autonomic nervous dysfunction such as anxiety, depression.Primary disease pathogenesis etiology is understood by medical science the most completely.Clinical medicine is observed and is thought: the outbreak of primary disease is relevant with the change of emotion.Often in anxiety, fear, depression or excitation time, make the function generation obstacle of higher nerve system cause autonomic nervous dysfunction, cause a kind of syndrome of gastrointestinal disease.Due to medically for primary disease without specific short, i.e. for the different manifestations of patient, symptomatic treatment can only be given frequently with Comprehensive Treatment.Western medical treatment is such as: stomachache person gives relieving spasm to stop pain medicine；Diarrhoea person gives diarrhea；Psychentonia, anxious person give tranquilizer etc.；But in most cases obstinate.The traditional Chinese medical science thinks gastrointestinal neurosis many genus incoordination between the liver and stomach, incoordination between the spleen and stomach in dialectical.Therefore, with invigorating spleen and reinforcing stomach, the depressed liver-energy dispersing and QI regulating disorderly relieving restlessness of reconciliation as therapeutic rules, although there being certain effect in traditional treatment, but effect is less desirable.Owing to not having specific short, illness is many, is clinical common difficult and complicated illness.Therefore, be badly in need of research and development a kind of good for gastrointestinal neurosis therapeutic effect, side effect is little, the medicine of low cost is very important.
In recent years, the related drugs about treatment gastrointestinal neurosis also has many reports.Such as: 1, Application No. 201010213489.2, the application for a patent for invention of entitled " a kind of prescription treating gastrointestinal neurosis ", this patent drug compositions is mainly made up of Radix Bupleuri, Fructus Gardeniae, Cortex Moutan, the Radix Paeoniae Alba, the Rhizoma Anemarrhenae, Fructus Aurantii Immaturus, Herba Dendrobii, Spica Prunellae, Pericarpium Citri Reticulatae, Pericarpium Citri Reticulatae Viride and Rhizoma Coptidis.2, Application No. 200410064767.7, the application for a patent for invention of entitled " a kind of prescription treating gastrointestinal neurosis, gastritis ", this application drug main to be made up of Radix Bupleuri, Radix Angelicae Sinensis, the Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, Rhizoma Zingiberis Recens and Herba Menthae, additionally adds oryzanol, vitamin B1 and diazepam.3, Application No. 200910229327.5, the patent of invention of entitled " Chinese medicine formula for the treatment of gastrointestinal neurosis ", the medicine of this patent application publication is made up of Radix Codonopsis, Poria, the Rhizoma Atractylodis Macrocephalae, Fructus Amomi, Semen Coicis, Pericarpium Citri Reticulatae, Seem Lablab Album, Rhizoma Dioscoreae, Rhizoma Zingiberis and Radix Glycyrrhizae.
Summary of the invention
The technical problem to be solved in the present invention is: provide a kind of pharmaceutical composition treating gastrointestinal neurosis.Utilizing Drug therapy gastrointestinal neurosis of the present invention, its therapeutic effect is good, side effect is less, and low cost.
In order to solve the problems referred to above, the technical solution used in the present invention is:
The present invention provides a kind of pharmaceutical composition treating gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is by Radix Codonopsis 9～15g, Rhizoma Atractylodis Macrocephalae (parched) 3～12g, the Radix Aucklandiae 3～10g and mebendazole 90～110mg composition.
According to the pharmaceutical composition of above-mentioned treatment gastrointestinal neurosis, representing with weight portion, described pharmaceutical composition is that the Radix Aucklandiae 3～10g and mebendazole 100mg forms by Radix Codonopsis 9～15g, Rhizoma Atractylodis Macrocephalae (parched) 3～12g.
According to the pharmaceutical composition of above-mentioned treatment gastrointestinal neurosis, representing with weight portion, described pharmaceutical composition is that the Radix Aucklandiae 5～8g and mebendazole 100mg forms by Radix Codonopsis 10～13g, Rhizoma Atractylodis Macrocephalae (parched) 5～10g.
According to the pharmaceutical composition of above-mentioned treatment gastrointestinal neurosis, the dosage form of the pharmaceutical composition of described treatment gastrointestinal neurosis is capsule.
Pharmaceutical composition according to above-mentioned treatment gastrointestinal neurosis, the preparation method for the treatment of gastrointestinal neurosis capsule is: the composition and ratio being first according to the treatment gastrointestinal neurosis pharmaceutical composition described in any of the above-described item prepares various raw materials, the Radix Codonopsis weighed, Rhizoma Atractylodis Macrocephalae (parched) and the Radix Aucklandiae are pulverized respectively, mix after pulverizing, gained mixed powder is carried out water extraction 2～3 times, during extraction, the addition of water is 8～10 times of three kinds of medicine total amounts；Merge the aqueous extract of 2～3 gained；Then according to gained extracting solution is concentrated by conventional method, being concentrated into relative density is 1.0～1.3；Gained concentrate is dried, pulverizes after drying, medicated powder and mebendazole mix homogeneously after gained pulverizing, load capsule, obtain medical treatment gastrointestinal neurosis capsule.
According to the pharmaceutical composition of above-mentioned treatment gastrointestinal neurosis, described capsule uses No. 2 capsules, loads medicated powder 0.25g in every seed lac capsule.
The present invention treats the instructions of taking of gastrointestinal neurosis capsule: every day 2 times, sooner or later services once, and before or after meals is taken, more than 12 years old and be grown up, each 3～4,6～each 2～3 of 12 years old child.Two courses for the treatment of Monday.
The pharmacological action of the various crude drug of the present invention is as follows:
Radix Codonopsis: property is put down, sweet in the mouth, there is invigorating the spleen and replenishing QI, strengthening spleen and tonifying lung, anticancer, blood pressure lowering, anti-hypoxia, effect of defying age, body immunity can also be strengthened, improve the activity of superoxide dismutase, strengthen the ability eliminating free radical, there is Gastrointestinal motility adjustment, antiulcer, gastric acid secretion inhibiting, the effect of reduction pepsin activity.It is applicable to the diseases such as deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, ulcer, anemia, dyspnea due to deficiency is coughed, interior-heat is quenched one's thirst.
Effective ingredient contained in Radix Codonopsis has excitation, energy enhancing body resistance to nervous system, can increase again erythrocyte and hemoglobin；Zinc contained therein can enhancing development and improve sexual function, containing polysaccharide, phenols, sterol, volatile oil, vitamin B1, B2, the necessary aminoacid of multiple human body, scutellarein glucosid, Saponin and Alkaloid, trace element etc..Nervous system is had excitation, can enhancing body resistance；There are Gastrointestinal motility adjustment, antiulcer, gastric acid secretion inhibiting, reduce the effects such as pepsin activity；A rabbit erythrocyte, hemoglobin can be made to increase, the leukopenia caused by chemotherapy, radiotherapy is had castering action；Peripheral vessels can be expanded and reduce blood pressure, adrenergic boosting can be suppressed again.
Rhizoma Atractylodis Macrocephalae (parched): this product has an invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, the effect such as antiabortive.The cards such as being usually used in insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.Medical evidence has and adjusts gastrointestinal motility function: Rhizoma Atractylodis Macrocephalae decocting liquid is relevant on functional status residing for the impact of rabbit motility of isolated ileocecal segment and intestinal tube.Having excitation under normal circumstances, when intestinal tube is in excitatory state by acetylcholine effect, the Rhizoma Atractylodis Macrocephalae is inhibitory action；When intestinal tube is in inhibitory state by epinephrine effect, the Rhizoma Atractylodis Macrocephalae, again in excitation, all can make intestinal tube activity recover to close to normal level.Antiulcer: the acetone extract gastric infusion of the Rhizoma Atractylodis Macrocephalae, has obvious inhibitory action to gastric mucosa damage caused by hydrochloric acid-ethanol.Through duodenal administration, pylorus-ligated rats gastric secretion there is is inhibitory action, reduce gastric acidity, reduce gastric acid and pepsic output.Enhancing human body immunity function: the Rhizoma Atractylodis Macrocephalae can be obviously enhanced the ability of leukocytes phagocytic staphylococcus aureus.
The Radix Aucklandiae: this product acrid in the mouth, hardship, warm in nature；Returning spleen, stomach, liver, large intestine channel, fragrance row dissipates, and can rise and can drop.This product mainly has following effect:
1, promoting the circulation of QI to relieve pain: for the abdominal distention caused by stagnation of QI in spleen and stomach, lack of appetite vomiting；
2, regulate the flow of vital energy soothing the liver: the hypochondriac pain caused for QI stagnation of the liver and galibladder；
3, spleen invigorating disappears stagnant: the stagnant gas of adjustable gastrointestinal.Treatment stomachache, diarrhoea, tenesmus.
The pungent temperature of this product is fragrant to be dissipated, and can rise and can drop, and leads to the gas of the gas managing three Jiao, especially benefaction gastrointestinal and pain relieving, has the merit of strengthening the spleen to promote digestion concurrently, and all cards caused by all taste QI stagnation of the large intestine are conventional product.
Antibacterial action: volatile oil 1:3000 concentration can suppress streptococcus, the golden yellow growth with white grapes, faint with diphtheria corynebacterium effect to escherichia coli；Total alkaloids is without antibacterial action.This savors decoct in addition to paratyphoid fever bacillus is had slight inhibitory action, invalid to 7 kinds of pathogenic bacterium such as staphylococcus aureus, dysentery bacterium.Separately having been reported that, decoct has inhibitory action to 10 kinds of funguses such as oidium schoenleinii and Mongolia's mutation thereof.
Mebendazole: mebendazole is a wide spectrum anthelmintic, inner or in vitro test all proves directly suppress the nematicide absorption to glucose, causes glycogen depletion, makes it to survive, have and significantly kill larva, the effect of suppression ovulation development, but do not affect blood in human body in sugar level.Can be used for preventing and treating the intestinal parasitical diseases such as ancylostome, ascarid, pinworm, whipworm, excrement class loop line worm.
Mebendazole, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae (parched), the Radix Aucklandiae in prescription of the present invention, have and remove the cause of disease, recovery gastrointestinal function of nervous system, invigorating the spleen and benefiting QI, promoting the circulation of QI to relieve pain, stomach function regulating relieving distension, the effect of promotion gastrointestinal function rehabilitation.Wherein mebendazole has anthelmintic, recovers the effect of gastrointestinal physiological function.Under physiological conditions: human body is a unified entirety, and each organ dysfunction is all under cerebral neural being uniformly coordinated, and restriction mutually coordinated, mutual reaches a kind of body health balancing and could safeguarding people.Gastrointestinal physiological function is also the vegetative nerve function of gastrointestinal.Vegetative nerve is not controlled just can be automatically adjusted the nerve of organ dysfunction by the consciousness meaning.That is it is not controlled by ideology, and the digestive and absorptive functions of its gastrointestinal just can oneself complete.Once certain cause of disease causes gastrointestinal dysfunction, dispels the cause of disease, and gastrointestinal dysfunction can recover normal, and disease just can rehabilitation.Clinical medicine proves that Enterozoa may result in gastrointestinal autonomic nervous dysfunction.Mebendazole can effectively kill larva, the effect of suppression ovulation development, and directly the suppression nematicide absorption to glucose, causes glycogen depletion, make it to survive.Prescription of the present invention passes through clinical practice for many years, uses mebendazole anthelmintic, dispels the cause of disease causing gastrointestinal dysfunction, recover gastrointestinal physiological function, observes highly effective to the treatment of gastrointestinal neurosis by clinical practice for many years.The traditional Chinese medical science is thought: gastric fullness, flatulence, belch, acid regurgitation, abdominal distention, stomachache, constipation diarrhoea or constipation that gastrointestinal neurosis causes are with diarrhoea replaces, feces band mucus is that gastrointestinal nerve dysfunction causes incoordination between the spleen and stomach, obstinate disease, caused by weakness of the spleen and stomach；And Radix Codonopsis, Rhizoma Atractylodis Macrocephalae (parched), the Radix Aucklandiae have invigorating the spleen and benefiting QI, promoting the circulation of QI to relieve pain, the effect such as stomach function regulating relieving distension.Radix Codonopsis has the effect of invigorating the spleen and benefiting QI, can improve gastro-intestinal digestion absorption function, adjustable gastric enteric nervous function, make the disease that causes of nerve of disorder be recovered.Rhizoma Atractylodis Macrocephalae (parched) with spleen invigorating, dampness, antidiarrheal as Main Function, by forefathers praise for " air making-up and spleen enlivening the first key medicine ", be usually used in insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels；The Radix Aucklandiae has promoting the circulation of QI to relieve pain, stomach function regulating relieving distension, the effect of antidiarrheal, share with Radix Codonopsis, Rhizoma Atractylodis Macrocephalae (parched), both replenishing QI to invigorate the spleen effect can have been strengthened, again can be to the disease good results such as the stomachache caused by incoordination between the spleen and stomach, diarrhoea, pipe abdomen fullness, medical evidence: the Radix Aucklandiae also has good result to gastrointestinal infection.Full side has the effect recovering gastrointestinal physiological function with promoting rehabilitation in a word, can take stopgap measures and can effect a permanent cure, have the dual function for the treatment of both the principal and secondary aspects of a disease.
The positive beneficial effect of the present invention:
1, the present invention treats the medicine of gastrointestinal neurosis, is for causing the pathogenesis etiology of gastrointestinal nerve dysfunction and advancing of disease and recovery process, from the angle of science by constantly groping to find out.The present invention treats gastrointestinal neurosis medicine and has the advantage for the treatment of both the principal and secondary aspects of a disease, and its effective percentage reaches more than 95%, and cure rate reaches more than 80%.Therefore, medicine of the present invention have be directed to the cause of disease, formula is simple, treatment time is short, be difficult to recurrence, side effect is little, low cost and other advantages.
2, the present invention is utilized to treat the medicine of gastrointestinal neurosis and the clinical material of capsule for treating gastrointestinal disease thereof:
Over more than 20 year, the present invention is utilized to treat gastrointestinal neurosis Chinese and western medicinal composition and patient 181 example of capsule for treating gastrointestinal function of nervous system thereof, male 111 examples, female 70 example, minimum 12 years old of age, maximum 81 years old.Take 78 examples that the present invention treats one course for the treatment of of capsule of gastrointestinal neurosis Chinese and western medicinal composition, take 103 examples that the present invention treats two courses for the treatment of of capsule of gastrointestinal neurosis Chinese and western medicinal composition.Wherein cure 151 examples, effective 21 examples, no effect 9.Cure rate reaches more than 80%, and total effective rate reaches 95%.Therefore, using Chinese and western medicinal composition of the present invention and capsule for treating gastrointestinal neurosis thereof, its therapeutic effect is notable.
The present invention treats the instructions of taking of gastrointestinal neurosis capsule: one day 2 times, the most once, before or after meals is taken, two weeks 1 courses for the treatment of；More than 12 years old and adult, each 3～4,6～each 2～3 of 12 years old child.
Model case:
Song, man, 65 years old, Zhumadian prefecture, Henan province city people from Xincai County, without diet bad habit, frequent gastric fullness flatulence, insomnia, brains dusk was swollen, and gastric fullness abdominal distention alleviates, and easily suffers from diarrhoea, and defecates three to four times on the one, is not the most careful in one's diet and i.e. recurs, extremity sleepiness.Wuhan PLA General Hospital is diagnosed as gastrointestinal neurosis through expert, in this three months poor effect of hospital's medication treatment.Carry out here treatment after being introduced, take medicine of the present invention i.e. to treat gastrointestinal neurosis capsule and i.e. have positive effect in second day, insomnia disappears, brains dusk swollen disappearance, abdominal distention gastric fullness alleviates, weak alleviate, continue again to take the present invention and treat gastrointestinal neurosis capsule (pharmaceutical formulation that this capsule uses is identical with embodiment 1 pharmaceutical formulation), treat two months, disease disappears, and stops treatment, follows up a case by regular visits to 4 years not recur.
Grandson, man, 62 years old, Zhumadian prefecture, Henan province city people from Shangcai County, without diet bad habit, frequent gastric fullness abdominal distention, stomachache has a sleepless night, inappetence, defecate shapeless but without mucus.Therefore, the informal dress medicine of some treatment gastrointestinal diseasies, weight time light during the state of an illness.It is diagnosed as gastrointestinal neurosis many years ago in BJ Union Hospital.Treat two months according to medication, taken a turn for the better, do not healed after treatment.Here treatment is carried out in the case for the treatment of is hopeless, take after medicine of the present invention i.e. treats gastrointestinal neurosis capsule three days, just feel insomnia, gastric fullness abdominal distention, shapeless improvement of defecating, continue again to take the present invention and treat after four courses for the treatment of of gastrointestinal neurosis capsule for treating (pharmaceutical formulation that this capsule uses is identical with embodiment 6 pharmaceutical formulation), above-mentioned disease disappears, and follows up a case by regular visits to without recurrence after 6 years.
Zhao, man, 23 years old, Zhumadian prefecture, Henan province city people from Pingyu County, seven or eight years old starts bad with regard to gastrointestinal, without diet bad habit, often gastric fullness abdominal distention, belch acid regurgitation, insomnia is tired, brains dusk is swollen, tinnitus, constipation abdomen is write alternately, band mucus of defecating, lassitude loin and legs, night sweat, seminal emission, sallow complexion, shortness of breath and palpitation, spirit is indigestion and loss of appetite, is diagnosed as chronic colitis at local county hospital.The best according to medication therapeutic effect at that time, take Spleen Invigorating and Intestine Tonifying Pill maintaining treatment.Later, the Zhumadian prefecture, Henan province First Five-Year Plan nine military hospital be diagnosed as stomach neurosis, irritable bowel syndrome.In hospitalize two weeks poor effect, oneself require to leave hospital.Take a little tranquilizer, enteritis, gastropathy medicine symptomatic treatment at ordinary times.After here is medical, the same day, gastrointestinal disease symptom alleviated, and insomnia eliminates, and has a rest good, within second day, just feels to take a favorable turn.Taking (pharmaceutical formulation that this capsule uses is identical with embodiment 8 pharmaceutical formulation) after the present invention treats two courses for the treatment of of gastrointestinal neurosis capsule continuously, normally, the medicine the most often taken also stopped sensory recovery, has rosy cheeks, and does not recurs so far.
Liu, female, 42 years old, from sensation morbidity more than 20 year, without diet bad habit, often insomnia, gastric fullness abdominal distention, constipation diarrhoea were alternately, extremity are aching and limp, brains is confused swollen；It is diagnosed as gastrointestinal neurosis in central hospital of Zhumadian City, has taken a turn for the better hospitalization fortnight, through a little tranquilizer of informal dress, gastrointestinal disease medicine after leaving hospital.Carry out here treatment after being introduced, take that the present invention treats gastrointestinal neurosis capsule second day insomnia, gastric fullness abdominal distention i.e. take a favorable turn, continue to take the present invention and treat after three courses for the treatment of of gastrointestinal neurosis capsule (pharmaceutical formulation that this capsule uses is identical with embodiment 11 pharmaceutical formulation), above-mentioned symptom disappears, so far within 8 years, feel good, recur the most again.
Chen, man, 29 years old, Zhumadian prefecture, Henan province city people from Pingyu County, without diet bad habit, disease time 2 years, insomnia, brains dusk is swollen, stomach still can, stool band mucus, defecate shapeless, the soft sleepiness of lower limb.It is diagnosed as chronic colitis, two months poor effect of hospitalize in the People's Hospital of Zhumadian City, oneself takes Spleen Invigorating and Intestine Tonifying Pill more than a year, defecate one day two to three times, occasionally have stomachache, do not heal.After treat in here, take the present invention and treat gastrointestinal neurosis capsule and within second day, just have a sleepless night disappearances, clearheaded, without bowel movement, the 3rd day stool normally, mucus minimizing.Taking (pharmaceutical formulation that this capsule uses is identical with embodiment 14 pharmaceutical formulation) after the present invention treats gastrointestinal neurosis capsule two weeks, conscious, disease disappears, withdrawal, follows up a case by regular visits to 12 years so far without recurrence.
Guo, female, 52 years old, Zhumadian prefecture, Henan province city people from Pingyu County, bad with regard to body constitution at an early age, without diet bad habit, inappetence；Often gastric fullness, abdominal distention, insomnia, brains dusk is swollen, limbs fatigue, often constipation, often suffers from diarrhoea, and stool is sometimes with mucus.Treat through local hospital, do not heal.After be diagnosed as gastrointestinal neurosis in Henan Prov. People's Hospital, merge chronic cholecystitis, after treatment, effect is undesirable.Rehabilitation to disease is lost confidence, often takes some medicines treating cholecystitis and treats the medicine of gastrointestinal disease to alleviate the state of an illness, is afraid of that abdominal distention dare not be had supper evening.Coming here after being introduced to go to a doctor, take after the present invention treats gastrointestinal neurosis capsule, that night, pipe abdomen fullness alleviated, and insomnia is alleviated.The rear present invention that continues to take medicine treats after two courses for the treatment of of gastrointestinal neurosis capsule (pharmaceutical formulation that this capsule uses is identical with embodiment 1 pharmaceutical formulation), appetite might as well, cholecystitis symptom also eliminates, defecate the most normal, through the thorough rehabilitation of examination in hospital, the medicine the most often eaten also stops, and within 15 years, does not recurs so far.
Detailed description of the invention:
The present invention is expanded on further below in conjunction with embodiment, but is not limiting as present disclosure.
Embodiment 1:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 12g, Rhizoma Atractylodis Macrocephalae (parched) 8g, Radix Aucklandiae 6g and mebendazole 100mg.
Embodiment 2:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 10g, Rhizoma Atractylodis Macrocephalae (parched) 5g, Radix Aucklandiae 4g and mebendazole 95mg.
Embodiment 3:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 14g, Rhizoma Atractylodis Macrocephalae (parched) 10g, Radix Aucklandiae 8g and mebendazole 105mg.
Embodiment 4:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 15g, Rhizoma Atractylodis Macrocephalae (parched) 12g, Radix Aucklandiae 10g and mebendazole 110mg.
Embodiment 5:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 9g, Rhizoma Atractylodis Macrocephalae (parched) 3g, Radix Aucklandiae 3g and mebendazole 90mg.
Embodiment 6:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 10g, Rhizoma Atractylodis Macrocephalae (parched) 10g, Radix Aucklandiae 8g and mebendazole 102mg.
Embodiment 7:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 13g, Rhizoma Atractylodis Macrocephalae (parched) 6g, Radix Aucklandiae 8g and mebendazole 92mg.
Embodiment 8:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 12g, Rhizoma Atractylodis Macrocephalae (parched) 7g, Radix Aucklandiae 8g and mebendazole 98mg.
Embodiment 9:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 10g, Rhizoma Atractylodis Macrocephalae (parched) 5g, Radix Aucklandiae 5g and mebendazole 100mg.
Embodiment 10:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 13g, Rhizoma Atractylodis Macrocephalae (parched) 10g, Radix Aucklandiae 8g and mebendazole 100mg.
Embodiment 11:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 12g, Rhizoma Atractylodis Macrocephalae (parched) 7g, Radix Aucklandiae 6g and mebendazole 100mg.
Embodiment 12:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 11g, Rhizoma Atractylodis Macrocephalae (parched) 9g, Radix Aucklandiae 7g and mebendazole 100mg.
Embodiment 13:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 10g, Rhizoma Atractylodis Macrocephalae (parched) 5g, Radix Aucklandiae 4g and mebendazole 100mg.
Embodiment 14:
The present invention treats the pharmaceutical composition of gastrointestinal neurosis, represents with weight portion, and described pharmaceutical composition is to be made up of Radix Codonopsis 10g, Rhizoma Atractylodis Macrocephalae (parched) 9g, Radix Aucklandiae 8g and mebendazole 100mg.
The preparation method of the embodiment of the present invention 1～14 treatment gastrointestinal neurosis capsule is:
The composition and ratio being first according to the treatment gastrointestinal neurosis pharmaceutical composition described in embodiment 1～14 any embodiment prepares various raw materials, the Radix Codonopsis weighed, Rhizoma Atractylodis Macrocephalae (parched) and the Radix Aucklandiae are pulverized respectively, mix after pulverizing, mixed raw material is put into pot and adds water soaking 20 minutes, the addition of water is 10 times of raw material gross weight, immersion post-heating steaming and decocting, boiled post-cooked 25～30 minutes, filter after boiling, obtain aqueous extract for the first time；Carry out 2 water again according to this water extracting method to carry, respectively obtain second time and third time aqueous extract；Merge the aqueous extract of 3 gained；Then according to gained extracting solution is concentrated by conventional method, being concentrated into relative density is 1.2；Gained concentrate is dried, pulverizes after drying, medicated powder and mebendazole mix homogeneously after gained pulverizing, load No. 2 capsules, every seed lac capsule loads medicated powder 0.25g, obtain medical treatment gastrointestinal neurosis capsule.
Claims (6)
1. the pharmaceutical composition treating gastrointestinal neurosis, it is characterised in that: described pharmaceutical composition is to be made up of Radix Codonopsis 9～15g, Rhizoma Atractylodis Macrocephalae (parched) 3～12g, the Radix Aucklandiae 3～10g and mebendazole 90～110mg.
The pharmaceutical composition for the treatment of gastrointestinal neurosis the most according to claim 1, it is characterised in that: described pharmaceutical composition is that the Radix Aucklandiae 3～10g and mebendazole 100mg is made by Radix Codonopsis 9～15g, Rhizoma Atractylodis Macrocephalae (parched) 3～12g.
The pharmaceutical composition for the treatment of gastrointestinal neurosis the most according to claim 1, it is characterised in that: described pharmaceutical composition is that the Radix Aucklandiae 5～8g and mebendazole 100mg is made by Radix Codonopsis 10～13g, Rhizoma Atractylodis Macrocephalae (parched) 5～10g.
The pharmaceutical composition for the treatment of gastrointestinal neurosis the most according to claim 1, it is characterised in that: the dosage form of the pharmaceutical composition of described treatment gastrointestinal neurosis is capsule.
The pharmaceutical composition for the treatment of gastrointestinal neurosis the most according to claim 4, it is characterized in that, the preparation method for the treatment of gastrointestinal neurosis capsule is: the composition and ratio being first according to the treatment gastrointestinal neurosis pharmaceutical composition described in any one of claims 1 to 3 prepares various raw materials, the Radix Codonopsis weighed, Rhizoma Atractylodis Macrocephalae (parched) and the Radix Aucklandiae are pulverized respectively, mix after pulverizing, gained mixed powder is carried out water extraction 2～3 times, during extraction, the addition of water is 8～10 times of three kinds of medicine total amounts；Merge the aqueous extract of 2～3 gained；Then according to gained extracting solution is concentrated by conventional method, being concentrated into relative density is 1.0～1.3；Gained concentrate is dried, pulverizes after drying, medicated powder and mebendazole mix homogeneously after gained pulverizing, load capsule, obtain medical treatment gastrointestinal neurosis capsule.
The pharmaceutical composition for the treatment of gastrointestinal neurosis the most according to claim 5, it is characterised in that: described capsule uses No. 2 capsules, loads medicated powder 0.25g in every seed lac capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410154453.XA CN103961391B (en) | 2014-04-17 | 2014-04-17 | A kind of pharmaceutical composition treating gastrointestinal neurosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410154453.XA CN103961391B (en) | 2014-04-17 | 2014-04-17 | A kind of pharmaceutical composition treating gastrointestinal neurosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103961391A CN103961391A (en) | 2014-08-06 |
| CN103961391B true CN103961391B (en) | 2016-08-31 |
Family
ID=51231713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410154453.XA Expired - Fee Related CN103961391B (en) | 2014-04-17 | 2014-04-17 | A kind of pharmaceutical composition treating gastrointestinal neurosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103961391B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796654B (en) * | 2016-04-05 | 2020-07-03 | 中国人民武装警察部队后勤学院 | Traditional Chinese medicine composition for treating diarrhea-predominant irritable bowel syndrome, navel patch and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1430999A (en) * | 2003-01-28 | 2003-07-23 | 南京师范大学 | Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product |
| CN102670702A (en) * | 2012-06-04 | 2012-09-19 | 黄芸 | Guangmuxiang traditional Chinese medicine oral liquid for treating chronic gastroenteritis and its preparation method |
| WO2013177067A3 (en) * | 2012-05-19 | 2014-01-16 | Zhao Aiping | Herbal composition for treatment of gastrointestinal inflammatory diseases and method to prepare and use thereof |
-
2014
- 2014-04-17 CN CN201410154453.XA patent/CN103961391B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1430999A (en) * | 2003-01-28 | 2003-07-23 | 南京师范大学 | Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product |
| WO2013177067A3 (en) * | 2012-05-19 | 2014-01-16 | Zhao Aiping | Herbal composition for treatment of gastrointestinal inflammatory diseases and method to prepare and use thereof |
| CN102670702A (en) * | 2012-06-04 | 2012-09-19 | 黄芸 | Guangmuxiang traditional Chinese medicine oral liquid for treating chronic gastroenteritis and its preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 健脾温中法治疗肠易激综合征;陈允旺;《陕西中医》;20020125(第01期);第40页 * |
| 痛泻要方加味治疗结肠易激综合征46例;曾秀池;《实用中医药杂志》;20100331;第26卷(第3期);第159页 * |
| 秋季驱蛔效果佳;刘吉;《开卷有益.求医问药》;20010915(第09期);第16-17页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103961391A (en) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102949630B (en) | Traditional Chinese medicine composition for treating abdominal distension caused by lack of gastrointestinal motility | |
| CN100528204C (en) | Medicament for treating children's infantile malnutrition symptom | |
| CN103948708B (en) | A kind of Chinese medicine for the treatment of restless legs syndrome | |
| CN103893329A (en) | Pharmaceutical composition for treating irritable bowel syndrome | |
| CN103495080B (en) | Traditional Chinese medicine for treating infantile anorexia | |
| CN103520649B (en) | The Chinese medicine for the treatment of facial neuritis | |
| CN103961391B (en) | A kind of pharmaceutical composition treating gastrointestinal neurosis | |
| CN103919895B (en) | The Chinese medicinal liquor of a kind of the intestines and stomach coordinating, treatment constipation | |
| CN103040975B (en) | Traditional Chinese medicine composition for nursing and treating infantile diarrhea | |
| CN104548021A (en) | Traditional Chinese medicine composition for assisting rehabilitation after chemoradiotherapy of cancer patients | |
| CN103751418A (en) | Traditional Chinese medicine composition for treating restless leg syndrome | |
| CN102205087B (en) | Chinese medicinal composition for treating chronic gastritis and preparation method thereof | |
| CN102626506B (en) | Traditional Chinese medicine for curing seroperitoneum | |
| CN101810751B (en) | Traditional Chinese medicine preparation for treating pediatric mesenteric lymph node inflammation | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN106075058A (en) | The health medicine that a kind of complement lengthens one's life | |
| CN105943753A (en) | Traditional Chinese medicinal composition for preventing and treating chronic fatigue syndrome | |
| CN104189766B (en) | One kind treats schizoid Chinese medicine composition | |
| CN105362596A (en) | Traditional Chinese medicine for treating pulmonary emphysema and preparation method thereof | |
| CN105362835A (en) | Traditional Chinese medicine composition for treating functional dyspepsia | |
| CN105343629B (en) | A kind of Chinese medicine composition and preparation method thereof for treating cardiac insufficiency | |
| CN105456995A (en) | Traditional Chinese medicine composition for treating neonatal jaundice | |
| CN105056194A (en) | Chinese herb composition for treating liver-qi stomach attacking and cold-heat mixed type chronic gastritis | |
| CN104208197B (en) | A kind of Chinese medicine pill treating children's's encephalitis | |
| CN103191338B (en) | Pharmaceutical composition for treating pediatric esophageal achalasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160831 Termination date: 20170417 |